Latest From Biotech Now

JOBS Act: Rule 506 Goes Into Effect Today

DC in Fall

Since Congress passed the Jumpstart our Business Startups (JOBS) Act last spring, there have been 39 IPOs in the biotech industry – and counting!  Today, another provision from the JOBS Act takes effect that will further enhance biotech capital formation. Pursuant to rules mandated by the JOBS Act, companies are now able to use general solicitation to advertise to investors when conducting an offering under Rule 506 of SEC Regulation D.  Rule 506 is a Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: ,

“Should the USPTO allow the patenting of living organisms?”

shutterstock_1092009

Most people associate patents with mechanical or electronic devices, new chemical substances, intricate machines or other inanimate things. The notion that patents are also available for living things may be puzzling at first. A patent is a form of property right that allows its owner a certain measure of control over how others may make, use or sell the patented invention. Surely the inventor of e.g. a new gyroscope sensor (like those used in Segway Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , ,

Congratulations to Gevo on the Construction of its New Demonstration Paraxylene Plant

Gevo

On Monday, August 26, 2013, Gevo, Inc., the world’s only commercial producer of bio-isobutanol, held a ribbon cutting ceremony for its demonstration-scale paraxylene plant in Silsbee, Texas.  BIO’s own CEO Jim Greenwood attended the ribbon cutting ceremony and had this to say: “Industrial biotechnology companies such as Gevo show the true scope and reach of American innovation and ingenuity. After you visit these companies, after you see how entrepreneurs like Gevo CEO Pat Gruber and his Read More >

Environmental & Industrial  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Ask CA Governor Brown To Sign SB 598

Jim Greenwood

California’s Assembly and Senate have both overwhelmingly passed Senate Bill 598, legislation that creates a pathway for the substitution of interchangeable biologic medicines. Despite fierce opposition from insurance companies and large pharmacy chains, it is now on its way to the Governor’s desk. It’s critical for him to understand that this issue is one of the highest priorities for patients, healthcare providers and the life sciences industry. Senate Bill 598 is needed now to update Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Investor Forum Company Snapshot: Opsona Therapeutics

opsona115x76

Opsona Therapeutics will be participating in the upcoming BIO Investor Forum, and will be giving a presentation on their work in the autoimmune/inflammatory diseases and oncology space (among other indications). To learn more about their company, please read one of our final company snapshots below. Company Snapshot What is your company’s lead product or technology? Opsona’s lead product OPN-305 is a fully humanized monoclonal IgG4 antibody targeting Toll-like-receptor-2 (TLR2), which is in clinical development as Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,